BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26360125)

  • 41. Beta Cell Function and Insulin Resistance After Conversion from Tacrolimus Twice-Daily to Extended-Release Tacrolimus Once-Daily in Stable Renal Transplant Recipients.
    Ruangkanchanasetr P; Sanohdontree N; Supaporn T; Sathavarodom N; Satirapoj B
    Ann Transplant; 2016 Dec; 21():765-774. PubMed ID: 27980321
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study.
    Boillot O; Seket B; Dumortier J; Pittau G; Boucaud C; Bouffard Y; Scoazec JY
    Liver Transpl; 2009 Nov; 15(11):1426-34. PubMed ID: 19877264
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Significant reduction of Tacrolimus trough level after conversion from twice daily Prograf to once daily Advagraf in Chinese renal transplant recipients with or without concomitant diltiazem treatment.
    Ma MK; Kwan LP; Mok MM; Yap DY; Tang CS; Chan TM
    Ren Fail; 2013 Aug; 35(7):942-5. PubMed ID: 23815459
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetic Study of Conversion Between 2 Formulations of Once-daily Extended-release Tacrolimus in Stable Lung Transplant Patients.
    Sintes H; Sáez-Giménez B; Berastegui C; López-Meseguer M; Monforte V; Bravo C; Vima J; Gómez-Ollés S; Roman A
    Transplantation; 2018 Oct; 102(10):e439-e446. PubMed ID: 29965950
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients.
    Alloway R; Steinberg S; Khalil K; Gourishankar S; Miller J; Norman D; Hariharan S; Pirsch J; Matas A; Zaltzman J; Wisemandle K; Fitzsimmons W; First MR
    Transplantation; 2007 Jun; 83(12):1648-51. PubMed ID: 17589351
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation.
    Takada Y; Kaido T; Asonuma K; Sakurai H; Kubo S; Kiuchi T; Inomata Y; Isaji S; Tsumura H; Teramukai S; Matsubara Y; Sakabayashi S; Uemoto S
    Liver Transpl; 2013 Aug; 19(8):896-906. PubMed ID: 23696054
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tacrolimus once-daily formulation: in the prophylaxis of transplant rejection in renal or liver allograft recipients.
    Cross SA; Perry CM
    Drugs; 2007; 67(13):1931-43. PubMed ID: 17722962
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Renal function and safety in stable kidney transplant recipients converted from immediate-release to prolonged-release tacrolimus.
    Lauzurica R; Morales JM; van Hooff J;
    Transpl Int; 2012 Jan; 25(1):48-55. PubMed ID: 21992068
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Switch from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in kidney transplantation.
    Iaria G; Sforza D; Angelico R; Toti L; de Luca L; Manuelli M; Bellini I; Manzia TM; Anselmo A; Tisone G
    Transplant Proc; 2011 May; 43(4):1028-9. PubMed ID: 21620043
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Early Conversion From Twice-Daily Tacrolimus to Prolonged-Release Tacrolimus in Liver Transplantation: A Single-Center Experience.
    Ogura Y; Imai H; Kamei H; Hori T; Kurata N; Onishi Y
    Ann Transplant; 2016 Jul; 21():448-55. PubMed ID: 27432248
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A 39-month follow-up study to evaluate the safety and efficacy in kidney transplant recipients treated with modified-release tacrolimus (FK506E)-based immunosuppression regimen.
    Han DJ; Park JB; Kim YS; Kim SJ; Ha J; Kim HC; Kim SJ; Moon IS; Yang CW
    Transplant Proc; 2012 Jan; 44(1):115-7. PubMed ID: 22310592
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and Efficacy of Conversion to Once-Daily Tacrolimus from Twice-Daily Tacrolimus in Pediatric Liver Transplant Recipients.
    An S; Lee S; Rhu J; Kim JM; Choi GS; Joh JW
    J Pediatr Surg; 2023 Oct; 58(10):2054-2058. PubMed ID: 37277238
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Favorable longterm outcomes of liver transplant recipients treated de novo with once-daily tacrolimus: Results of a single-center cohort.
    Gastaca M; Valdivieso A; Bustamante J; Fernández JR; Ruiz P; Ventoso A; Testillano M; Palomares I; Salvador P; Prieto M; Montejo M; Suárez MJ; de Urbina JO
    Liver Transpl; 2016 Oct; 22(10):1391-400. PubMed ID: 27434676
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Once-daily, prolonged-release tacrolimus vs twice-daily, immediate-release tacrolimus in de novo living-donor liver transplantation: A Phase 4, randomized, open-label, comparative, single-center study.
    Shin MH; Song GW; Lee SG; Hwang S; Kim KH; Ahn CS; Moon DB; Ha TY; Jung DH; Park GC; Yun YI; Kim WJ; Kang WH; Kim SH; Jiang H; Lee S; Tak EY
    Clin Transplant; 2018 Sep; 32(9):e13376. PubMed ID: 30098071
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pilot Study Comparing the Efficacy, Safety, Convertibility, and Tacrolimus Trough Levels of Twice-Daily Tacrolimus (Prograf) to Once-Daily Tacrolimus (Advagraf) Among Standard-Risk Kidney Transplant Patients at the National Kidney and Transplant Institute.
    Danguilan RA; Lamban A; Pamugas GEP
    Transplant Proc; 2019 Oct; 51(8):2615-2619. PubMed ID: 31563241
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A prospective randomized open study in liver transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids.
    Otero A; Varo E; de Urbina JO; Martín-Vivaldi R; Cuervas-Mons V; González-Pinto I; Rimola A; Bernardos A; Otero S; Maldonado J; Herrero JI; Barrao E; Domínguez-Granados R
    Liver Transpl; 2009 Nov; 15(11):1542-52. PubMed ID: 19877219
    [TBL] [Abstract][Full Text] [Related]  

  • 57. First clinical experience with the new once-daily formulation of tacrolimus.
    First MR
    Ther Drug Monit; 2008 Apr; 30(2):159-66. PubMed ID: 18367975
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of switching from twice-daily to once-daily tacrolimus formulation on quality of life, anxiety, and transplant benefit perception after kidney transplantation.
    Calia R; Lai C; Aceto P; Luciani M; Romagnoli J; Lai S; Gargiulo A; Citterio F
    Transplant Proc; 2011 May; 43(4):1020-3. PubMed ID: 21620041
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation.
    Trunečka P; Boillot O; Seehofer D; Pinna AD; Fischer L; Ericzon BG; Troisi RI; Baccarani U; Ortiz de Urbina J; Wall W;
    Am J Transplant; 2010 Oct; 10(10):2313-23. PubMed ID: 20840481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.